Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract analysis organisation (CRO) and drug discovery firm, has promoted Clare Rutty to CFO and welcomes two new hires in Sue Peffer as Head of Marketing and Leanne Clarke as HR Officer. Following the latest announcement of new fairness financing, these appointments strengthen the management group, guaranteeing a powerful basis because the Company units its sights on continued development.
Already a longtime colleague, Clare Rutty has been promoted to Chief Financial Officer (CFO). Since becoming a member of Metrion, Clare has been instrumental in progressing the reporting and monetary controls because the enterprise has grown from reported turnover of £1.5m within the monetary yr to thirty first December 2018 to £5.3m within the yr to thirty first December 2022, with additional development in 2023.
Since 2022 the Metrion group has grown by 55% to 42 staff, and the enterprise has established new companies and income strains. Clare was carefully concerned within the £2.7m new fairness funding spherical in 2021 led by Gresham House Ventures and extra lately within the £3.7m of latest fairness financing led by Maven Capital Partners, which closed in December 2023.
In the brand new position of Head of Marketing, Sue Peffer will handle all advertising actions. Sue has a background in advertising within the life sciences sector, together with at Cresset, a computational chemistry software program and companies firm, Capsugel (now Lonza), and The Automation Partnership (now Sartorius Stedim Biotech). Sue’s appointment additionally boosts feminine illustration on the Metrion Leadership Team.
As a companies firm, Metrion’s workers are its most beneficial asset. In the brand new position of Human Resources Officer, Leanne Clarke will guarantee Metrion attracts prime expertise and maintains a office the place everybody can attain their full potential.
“Ensuring Metrion appoints staff of the highest calibre is paramount to our success. We are also proud that women currently make up 42% of Metrion employees – well over the 39% average for women working in UK drug discovery R&D1. These new appointments and Clare’s promotion are reflective of the growth and increasing maturity of our business, and in line with our goal of equal representation within our workforce.”
Dr Andrew Southan, Chief Executive, Metrion Biosciences
“I’m pleased to join the Board at the time of closing the 2023 funding round and look forward to working with the directors and the wider Metrion team as the business continues to develop.”
Clare Rutty, CFO, Metrion Biosciences
“I’m delighted to join Metrion at this exciting time for the business. To do so at the point when other female colleagues are promoted and welcomed makes me proud to be part of an organisation that recognises female talent.”
Sue Peffer, Head of Marketing, Metrion Biosciences
“I am thrilled to join Metrion and am eager to contribute to its continued growth and success in a highly challenging market. I am excited to collaborate with the talented team and foster a supportive environment in which employees can thrive and contribute to advancements in the biosciences field.”
Leanne Clarke, HR Officer, Metrion Biosciences
For extra data: https://www.metrionbiosciences.com/.